APOO is a newly discovered apolipoprotein that is upregulated in the hearts of diabetic patients and animal models of diabetes. Overexpression of APOO in mouse heart models and cardiac cell lines leads to mitochondrial dysfunction, increased fatty acid uptake and triglyceride accumulation, oxidative stress, and apoptosis. This suggests that APOO may play a role in mediating lipotoxic effects and the development of diabetic cardiomyopathy through promoting mitochondrial dysfunction when lipid uptake exceeds oxidative capacity.
Creative Enzymes is a worldwide leading company in diagnostic enzymes manufacturing and supply. We are committed to providing our customers with diverse enzyme products and custom enzyme-related services for medical and research diagnosis. Relying on our professional team and state-of-art technologies, we have gained solid reputation for having top of the line products and services. https://diagnostic-enzymes.creative-enzymes.com/
ALT is an enzyme present in liver, heart skeletal muscles, highest concentration is present in Liver. it value increases when there is abnormality in liver, ALT is an amino transferase which transfer one amino group from an amino acid and transfer to another substance for production of non essential amino acid
Creative Enzymes is a worldwide leading company in diagnostic enzymes manufacturing and supply. We are committed to providing our customers with diverse enzyme products and custom enzyme-related services for medical and research diagnosis. Relying on our professional team and state-of-art technologies, we have gained solid reputation for having top of the line products and services. https://diagnostic-enzymes.creative-enzymes.com/
ALT is an enzyme present in liver, heart skeletal muscles, highest concentration is present in Liver. it value increases when there is abnormality in liver, ALT is an amino transferase which transfer one amino group from an amino acid and transfer to another substance for production of non essential amino acid
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
Several distinct types of DM are caused by a complex interaction of genetics and environmental factors.
Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production.
The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMPraveen Nagula
DIABETES IS ONE OF THE MOST COMMON NONCOMMUNICABLE DISEASES WORLD WIDE.
EVERY 6 SECONDS ONE PERSON IS AFFECTED BY DIABETES..
THEME FOR 2014-2016
LETS UNITE FOR DIABETES
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Proteintech offers a wide range of markers
and related antibodies for cardiovascular research.
Slideshow includes:
Age-associated Changes in Cardiovascular Tissues
mTOR in Cardiac Physiology and Disease
Cardiac Troponin T Antibody
Cardio-related Antibodies
Survival of Esophageal Cancer Patients was Significantly Superior in Comparison with Cardioesophageal Cancer Patients after Surgery
Kshivets Oleg Surgery Department, Roshal Hospital, Moscow, Russia
OBJECTIVE: This study aimed to determine localization influence of tumor for 5-year survival (5YS) of esophageal (EC) or cardioesophageal (CC) cancer patients (ECP, CEP) after complete en block (R0) esophagogastrectomies (EG) through left/right thoracoabdominal incision.
METHODS: We analyzed data of 543 consecutive patients (age=56.4±8.8 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2019 (m=405, f=138; ECP=259, CEP=284; esophagogastrectomies (EG) Garlock=280, EG Lewis=263, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=151; adenocarcinoma=308, squamous=225, mix=10; T1=126, T2=114, T3=178, T4=125; N0=275, N1=69, N2=199; G1=157, G2=139, G3=247; early EC=107, invasive=436; only surgery=420, adjuvant chemoimmunoradiotherapy-AT=123: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 1892.4±2241 days and cumulative 5-year survival (5YS) reached 51.9%, 10 years – 45.7%, 20 years – 33.5%. 183 ECP lived more than 5 years (LS=4311±2419.7 days), 98 ECP – more than 10 years (LS=5903.4±2299.4 days). 224 died because of EC/CC (LS=629.2±320.1 days). 5YS of ECP (67.3%, LS=2605±2628.9 days) was significantly superior in comparison with CEP (36.4%, LS=1242.6±1558.5 days) (P=0.00000 by log-rank test). AT significantly improved 5YS (68.2% vs. 48.5%) (P=0.00033 by log-rank test). Cox modeling displayed that 5YS of ECP/CEP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen, blood group, Rh, glucose, protein (P=0.000-0.008). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT early-invasive EC (rank=2), PT N0—N12 (rank=3), erythrocytes/CC (4), thrombocytes/CC (5), stick neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
Several distinct types of DM are caused by a complex interaction of genetics and environmental factors.
Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production.
The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMPraveen Nagula
DIABETES IS ONE OF THE MOST COMMON NONCOMMUNICABLE DISEASES WORLD WIDE.
EVERY 6 SECONDS ONE PERSON IS AFFECTED BY DIABETES..
THEME FOR 2014-2016
LETS UNITE FOR DIABETES
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Proteintech offers a wide range of markers
and related antibodies for cardiovascular research.
Slideshow includes:
Age-associated Changes in Cardiovascular Tissues
mTOR in Cardiac Physiology and Disease
Cardiac Troponin T Antibody
Cardio-related Antibodies
Survival of Esophageal Cancer Patients was Significantly Superior in Comparison with Cardioesophageal Cancer Patients after Surgery
Kshivets Oleg Surgery Department, Roshal Hospital, Moscow, Russia
OBJECTIVE: This study aimed to determine localization influence of tumor for 5-year survival (5YS) of esophageal (EC) or cardioesophageal (CC) cancer patients (ECP, CEP) after complete en block (R0) esophagogastrectomies (EG) through left/right thoracoabdominal incision.
METHODS: We analyzed data of 543 consecutive patients (age=56.4±8.8 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2019 (m=405, f=138; ECP=259, CEP=284; esophagogastrectomies (EG) Garlock=280, EG Lewis=263, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=151; adenocarcinoma=308, squamous=225, mix=10; T1=126, T2=114, T3=178, T4=125; N0=275, N1=69, N2=199; G1=157, G2=139, G3=247; early EC=107, invasive=436; only surgery=420, adjuvant chemoimmunoradiotherapy-AT=123: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 1892.4±2241 days and cumulative 5-year survival (5YS) reached 51.9%, 10 years – 45.7%, 20 years – 33.5%. 183 ECP lived more than 5 years (LS=4311±2419.7 days), 98 ECP – more than 10 years (LS=5903.4±2299.4 days). 224 died because of EC/CC (LS=629.2±320.1 days). 5YS of ECP (67.3%, LS=2605±2628.9 days) was significantly superior in comparison with CEP (36.4%, LS=1242.6±1558.5 days) (P=0.00000 by log-rank test). AT significantly improved 5YS (68.2% vs. 48.5%) (P=0.00033 by log-rank test). Cox modeling displayed that 5YS of ECP/CEP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen, blood group, Rh, glucose, protein (P=0.000-0.008). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT early-invasive EC (rank=2), PT N0—N12 (rank=3), erythrocytes/CC (4), thrombocytes/CC (5), stick neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
Cortisol: Friend or Foe, An Overview of Cushing's Disease and Addison's Diseaseupstatevet
Title: Cortisol: Friend or Foe, An Overview of Cushing's Disease and Addison's Disease
Presented By: Erica Hunt, LVT, VTS
Description: This lecture will review the physiology of Cushing's and Addison's disease so that the technician can better understand the disease processes. We will also discuss different treatment options and the necessary monitoring.
hemichannel makes it a major contributor toionic dysregulaSusanaFurman449
hemichannel makes it a major contributor to
ionic dysregulation in ischemia. Second, Px1
hemichannel opening may result in efflux of
glucose and adenosine triphosphate (ATP),
further compromising the neuron_s recovery
from an ischemic insult. Consistent with this
was our observation that fluorescent dyes
became membrane-permeable only during
OGD. Hemichannels are putative conduits for
ATP release from astrocytes (21) and in the
cochlea (22). Third, the large amplitude of
the Px1 hemichannel current at holding po-
tentials near the neuron_s resting membrane
potential (È –60 mV) indicates that these
currents likely contribute substantially to
Banoxic depolarization,[ a poorly understood
but well-recognized and key component of
ischemic neuronal death (2, 23, 24). There-
fore, hemichannel opening may be an impor-
tant new pharmacological target to prevent
neuronal death in stroke.
References and Notes
1. A. J. Hansen, Physiol. Rev. 65, 101 (1985).
2. P. Lipton, Physiol. Rev. 79, 1431 (1999).
3. M. Kamermans et al., Science 292, 1178 (2001).
4. J. E. Contreras et al., Proc. Natl. Acad. Sci. U.S.A. 99, 495
(2002).
5. R. P. Kondo, S. Y. Wang, S. A. John, J. N. Weiss,
J. I. Goldhaber, J. Mol. Cell. Cardiol. 32, 1859 (2000).
6. H. Li et al., J. Cell Biol. 134, 1019 (1996).
7. L. Bao, S. Locovei, G. Dahl, FEBS Lett. 572, 65
(2004).
8. R. Bruzzone, M. T. Barbe, N. J. Jakob, H. Monyer,
J. Neurochem. 92, 1033 (2005).
9. R. Bruzzone, S. G. Hormuzdi, M. T. Barbe, A. Herb,
H. Monyer, Proc. Natl. Acad. Sci. U.S.A. 100, 13644
(2003).
10. See supporting material on Science Online.
11. J. Gao et al., Neuron 48, 635 (2005).
12. M. Aarts et al., Cell 115, 863 (2003).
13. C. Tomasetto, M. J. Neveu, J. Daley, P. K. Horan, R. Sager,
J. Cell Biol. 122, 157 (1993).
14. G. Feng et al., Neuron 28, 41 (2000).
15. A. Nimmerjahn, F. Kirchhoff, J. N. Kerr, F. Helmchen,
Nat. Methods 1, 31 (2004).
16. G. Sohl, S. Maxeiner, K. Willecke, Nat. Rev. Neurosci. 6,
191 (2005).
17. J. C. Saez, M. A. Retamal, D. Basilio, F. F. Bukauskas,
M. V. Bennett, Biochim. Biophys. Acta 1711, 215 (2005).
18. R. J. Thompson, M. H. Nordeen, K. E. Howell,
J. H. Caldwell, Biophys. J. 83, 278 (2002).
19. M. L. Fung, G. G. Haddad, Brain Res. 762, 97 (1997).
20. H. Benveniste, J. Drejer, A. Schousboe, N. H. Diemer,
J. Neurochem. 43, 1369 (1984).
21. C. E. Stout, J. L. Costantin, C. C. Naus, A. C. Charles,
J. Biol. Chem. 277, 10482 (2002).
22. H. B. Zhao, N. Yu, C. R. Fleming, Proc. Natl. Acad. Sci.
U.S.A. 102, 18724 (2005).
23. T. R. Anderson, C. R. Jarvis, A. J. Biedermann, C. Molnar,
R. D. Andrew, J. Neurophysiol. 93, 963 (2005).
24. G. G. Somjen, Physiol. Rev. 81, 1065 (2001).
25. Supported by the Canadian Institutes for Health Research
and the Canadian Stroke Network. B.A.M. has a Tier 1
Canada Research Chair in Neuroscience and a Michael
Smith Foundation for Health Research distinguished
scholar award. We thank Y.-T. Wang, C. C. Naus, and
T. Snutch for critical re ...
Calpain Inhibitors and Modulation of Ischaemia Reperfusion Induced Apoptosis ...iosrjce
IOSR Journal of Pharmacy and Biological Sciences(IOSR-JPBS) is a double blind peer reviewed International Journal that provides rapid publication (within a month) of articles in all areas of Pharmacy and Biological Science. The journal welcomes publications of high quality papers on theoretical developments and practical applications in Pharmacy and Biological Science. Original research papers, state-of-the-art reviews, and high quality technical notes are invited for publications.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
10. Discovery of a new apolipoprotein: APOO
obese heart Control heart Cloning of the human ortholog
« New » protein:
(Philip-Couderc P., Hypertension, 2003)
Differential expression in the
obese heart
9 weeks HFD
cDNA SEQUENCING
11 genes with
unknown function
We named : APOO
- Secreted protein
- Apolipoproteins’ family
14. APOO is overexpressed in human diabetic heart
(Lamant, J. Biol. Chem, 2006)
Ø Up-regulated in diabetic hearts.
What is the role of
cardiac APOO
overexpression?
Diabetic transgenic mice
Overexpressing APOB in heart
Reduced Lipid stores in heartLipid stores in heart
Reduced Apoptosis
Improved cardiac functionImproved cardiac function
Nielsen et al, JBC (2002)
Protection from « Lipoapoptosis »Protection from « Lipoapoptosis »
18. TEM of myocardial sections of mouse heart after HFD.
WT APOO-Tg
x10,000 x15,000
APOO overexpression induces myocardium
disorganization and mitochondrial swelling
19. -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.5 1.0 1.5 2.0 2.5 3.0 3.5
-2.0
-1.5
-1.0
-0.5
0.5
1.0
1.5
2.0Oxydative phosphorylation
Mitochondrial dysfunction
P < 0.0001
r = 0.7621 P < 0.0001
r = 0.7757
Mean APOO
expression (A.U.)
Meangenes
expression(A.U.)
NDUFA2
NDUFA3
NDUFA6
NDUFA8
NDUFAB1
NDUFB10
NDUFB11
NDUFB2
NDUFB5
NDUFB8
NDUFS2
NDUFS4
NDUFS7
NDUFV1
NDUFV3
SDHA
SDHB
SDHC
SDHD
UQCRB
UQCRC2
UQCRFS1
UQCRH
CYC1
CYCS
COX11
COX15
COX17
COX4I2
COX5B
COX6A2
COX7A2
COX7A2L
COX7C
ATP5C1
ATP5J
0
2
4
6
8
10
12
14
16
18
20
22
C I C II C III C IV C V
Meanexpressionlevel(A.U.)
Low APOO
High APOO
Data mining on 107 human heart
microarrays from GEO database
27. • PPAR is a transcription factor involved in lipid uptake.
• Ppara overexpression in mice led to cardiac dysfunction.
• The expression and activity of PPAR increase in diabetic
hearts.
• The increase in intracellular lipid content in APOO models,
should be associated with an induction of the expression of
PPAR
Are APOO models mimicking diabetic cardiomyopathy?
Finck BN, et al. J Clin Invest. 2002
29. • PGC-1 , a master regulator of mitochondrial biogenesis, is
upregulated in diabetic heart
• Ultrastructural analyses have revealed mitochondrial damage
in mouse models of the metabolic syndrome and in models of
type 1 and type 2 diabetes.
Are APOO models mimicking diabetic cardiomyopathy?
Handschin C. et al. Endocr. Rev. 2006
30. Mitochondrial degradation in APOO cells
0 5 10 15 20 25
0
2
4
6
8
r = 0.81 P < 0.0001
Apoo mRNA (A.U.)
Pgc1amRNA(A.U.)
Mouse heart
Human heart
0 0.2 0.4 0.6 0.8
2
4
6
8
10
12 r= 0.63 P = 0.0002
mRNA(A.U.)PGC-1A
APOO mRNA (A.U.)
nM
nM
nM
N
Control +100µM palmitate
aM
mf
mF
N
APOO + 100µM palmitate
mf
mF
0.0
0.5
1.0
1.5
2.0
2.5
***
ATP/AMPratio
Cont. APOO
PPARPPAR
Multilamellar
bodies
32. INSERM UMR 1048 Team 7
Toulouse University Hospital
Dr Philippe Rouet, PhD
Prof. Galinier, MD-PhD
Prof. C. Dambrin, MD-PhD
Dr P. Massabuau, MD
Dr M.Berry, MD
M. Barutaut
M. F. Evaristi
Dr C. Caubère,
Dr A. Turkieh,
Dr. V. Le Berre, PhD
Dr S. Sokol, PhD
L. Trouilh
Toulouse Genopole and Genotoul Network
Cardiology Federation
Acknowledgments
